Home › Compare › SCNLF vs EQR

SCNLF vs EQR: Dividend Comparison 2026

SCNLF yields 1373.63% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCNLF wins by $315919182.73M in total portfolio value
10 years
SCNLF
SCNLF
● Live price
1373.63%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$315919182.78M
Annual income
$276,344,297,604,930.75
Full SCNLF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — SCNLF vs EQR

📍 SCNLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCNLFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCNLF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SCNLF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCNLF
Annual income on $10K today (after 15% tax)
$116,758.24/yr
After 10yr DRIP, annual income (after tax)
$234,892,652,964,191.12/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, SCNLF beats the other by $234,892,652,959,536.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCNLF + EQR for your $10,000?

SCNLF: 50%EQR: 50%
100% EQR50/50100% SCNLF
Portfolio after 10yr
$157959591.41M
Annual income
$138,172,148,805,203.17/yr
Blended yield
87.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

SCNLF
No analyst data
Altman Z
-12.0
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCNLF buys
0
EQR buys
0
No recent congressional trades found for SCNLF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCNLFEQR
Forward yield1373.63% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$315919182.78M ✓$47.8K
Annual income after 10y$276,344,297,604,930.75 ✓$5,475.61
Total dividends collected$313011682.66M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: SCNLF vs EQR ($10,000, DRIP)

YearSCNLF PortfolioSCNLF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$148,063$137,362.64$11,380$679.82+$136.7K → SCNLF
2$2,059,200$1,900,773.30$13,014$837.25+$2.05M → SCNLF
3$26,909,187$24,705,842.24$14,961$1,036.20+$26.89M → SCNLF
4$330,522,388$301,729,558.78$17,297$1,289.22+$330.51M → SCNLF
5$3,817,312,082$3,463,653,126.46$20,121$1,613.15+$3817.29M → SCNLF
6$41,470,385,979$37,385,862,050.80$23,561$2,030.84+$41470.36M → SCNLF
7$423,953,934,089$379,580,621,092.34$27,783$2,573.54+$423953.91M → SCNLF
8$4,080,240,641,140$3,626,609,931,664.44$33,013$3,284.39+$4080240.61M → SCNLF
9$36,985,873,996,458$32,620,016,510,437.74$39,547$4,223.51+$36985873.96M → SCNLF
10$315,919,182,781,141$276,344,297,604,930.75$47,791$5,475.61+$315919182.73M → SCNLF

SCNLF vs EQR: Complete Analysis 2026

SCNLF — Stock

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Full SCNLF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this SCNLF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCNLF vs SCHDSCNLF vs JEPISCNLF vs OSCNLF vs KOSCNLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.